Own-label distributor

Under 21 CFR 111.3, an own-label distributor is defined as 'a person who puts its name on a label of a packaged and labelled dietary supplement that was packaged and labelled by another person.' In practice that includes virtually every supplement brand company that does not own a manufacturing site — the Amazon-private-label seller, the practitioner brand, the multi-level-marketing brand, the celebrity-endorsed brand, and the mature consumer brand whose contract manufacturer makes the actual product.

FDA has consistently interpreted this rule to mean that an OLD must either (a) personally comply with every Part 111 obligation, or (b) have a written quality agreement that delegates specific operational obligations to the contract manufacturer while retaining the OLD's own oversight, review, and ultimate accountability. Option (a) is almost never what brand owners actually do, and option (b) is what FDA expects to find on inspection — a quality agreement plus active oversight, not a quality agreement filed and forgotten.

• QC-unit responsibility for finished-product disposition (§111.105). Even if the contract manufacturer's QC does the work, the OLD remains accountable.
• Product complaint handling under Subpart O (§§111.553–.570) — complaints arrive at the brand owner.
• Serious adverse-event reporting under DSNDCPA (15-business-day MedWatch 3500A) — the AE reporting entity is the brand on the label.
• Recall execution and notification — the brand owner is the registered recall coordinator.
• Label content and claim substantiation under §403(r)(6) — the contract manufacturer prints what the brand specifies.
• FSMA facility registration if the OLD also holds or distributes — separate from the manufacturer's registration.
• Maintaining or having access to the MMR and BPR for every lot bearing their label (§§111.205–.210 + Subpart J).

FDA's 2016 Quality Agreements guidance (written for drugs but consistently applied by inspectors to supplements) sets the expected structure: a signed bilateral document that allocates each Part 111 subpart's obligations between OLD and contract manufacturer using an unambiguous mechanism such as a RACI matrix. The agreement must address: change control (who can change a formula, label, supplier), incoming material qualification, in-process release authority, finished-product release authority, complaint flow-down (CM must notify OLD within X days of receipt), AE flow-down (CM must notify OLD within 5 business days of any potentially serious AE), batch record access and retention (OLD gets a copy of the executed BPR for every lot), audit rights, and recall coordination.

Importantly, a quality agreement is NOT a liability waiver — FDA's position is that obligations can be allocated but ultimate Part 111 responsibility remains shared, with the OLD specifically retained by §111.12(a).

• No quality agreement at all — the most common pattern. Brand has a purchase order with the contract manufacturer and nothing else.
• Quality agreement exists but is silent on key items (complaints, AE flow-down, batch record access, recall coordination).
• Brand owner cannot produce the MMR for their product when FDA inspects them — the contract manufacturer 'has it' but the brand has never seen it.
• AE reports being held by the contract manufacturer and never escalated to the brand — both parties get a Warning Letter.
• Complaints handled entirely by the contract manufacturer's customer service, never logged at the brand, never tied to a 111.560 investigation decision.
• Brand changes the label (adds a new claim, changes serving size) without going through change control — the manufacturer ships against an outdated MMR.
• Brand assumes that 'GMP certified' contract manufacturer status (NSF, NPA, USP) substitutes for their own §111.12(a) obligations. It does not.

The fastest-growing OLD failure pattern is the Amazon-FBA private-label brand: a small operator who sources a white-label supplement from an overseas or domestic contract manufacturer, applies their brand label, and sells through a major online marketplace. FDA has issued multiple Warning Letters in 2023–2025 to such brand owners citing §111.12(a) — the brand owner often had no quality agreement, no MMR access, no complaint log, no AE-reporting plan, and no facility registration. The brand owner's defence ('the manufacturer is responsible') was rejected in every case. If your name is on the label and the product is sold in the US, you are an OLD.

• Signed quality agreement with every contract manufacturer covering all the items above.
• Documented qualified-supplier program — the contract manufacturer is itself a 'supplier' under Subpart E and must be qualified, with audits on a defined cadence.
• Brand-side QC representative (employee or qualified consultant) who reviews and signs off on every executed BPR before release.
• MMR archived at the brand for every product, kept synchronised with the version the contract manufacturer is running.
• Complaint log + 111.560 investigation procedure operated at the brand, with a defined SLA from contract manufacturer to brand.
• AE reporting plan with a designated DSNDCPA reporter at the brand, and a 5-business-day SLA from contract manufacturer to brand for AE notifications.
• Annual on-site or virtual audit of the contract manufacturer's Part 111 system, with audit report archived at the brand.
• Change-control procedure covering formula, label, supplier, and process changes — initiated by either party, approved by both.

• Tenant-type flag (manufacturer | own_label_distributor | both) drives the feature set.
• Supplier register with quality-agreement attachment, audit-cadence, last-audit date and next-audit due.
• Brand portal: per-customer scoped view into the contract manufacturer's Part 111 record set.
• Complaint + AE log with bilateral SLA tracker (contract manufacturer ↔ brand acknowledgement clock).
• Change-control workflow with both-parties approval gate.
• FDA-inspection mode renders an OLD-specific compliance pack: agreements, MMRs accessed, complaints, AE reports, audit reports.